Simple noninvasive tests for the detection of advanced liver fibrosis in patients with chronic hepatitis B

Simple noninvasive tests for the detection of advanced liver fibrosis in patients with chronic... Letter to the Editor 3.25 (high cutoff values) to distinguish F0–F2 and F3–F4 Simple noninvasive tests for the detection of for FIB-4 [1]. However, the above thresholds of APRI and advanced liver fibrosis in patients with chronic FIB-4 are recommended for diagnosing significant fibrosis hepatitis B (≥ F2) rather than advanced fibrosis (F3–F4) in the WHO guidelines for CHB [5]. Thus, the results might be biased if a c d b a Rui Huang , Xiang-An Zhao , Jian Wang , Yingying Hao and Chao Wu , a b the authors used these thresholds for diagnosing advanced Departments of Infectious Diseases, Intensive Care Unit, Nanjing Drum Tower fibrosis (F3–F4). Hospital, Nanjing University Medical School, Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Therefore, large-scale studies with well-defined inclusion Medicine, Nanjing University of Chinese Medicine and Department of Infectious and exclusion criteria are required to validate the diagnostic Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical accuracy of NITs and establish optimal thresholds for the University, Nanjing, Jiangsu Province, China detection of different fibrosis stages in CHB patients. Correspondence to Chao Wu, MD, PhD, Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School, 321 Zhongshan Acknowledgements Road, Nanjing 210008, Jiangsu Province, China Tel: + 86 258 310 5890; fax: + 86 258 330 7115; e-mail: dr.wu@nju.edu.cn The study was supported from the National Natural Science Foundation of China (81672025 and 81702011), Medical Science and Technology Development Foundation of Received 11 October 2017 Accepted 12 October 2017 Nanjing (ZDX16004 and YKK16118), Jiangsu Provincial Medical Innovation Team (CXTDA2017005), Natural We read with great interest the article by Lang et al. [1] in Science Foundation of Jiangsu Province for Young Scholar which they analyzed the diagnostic performance of simple (BK20160121), and Nanjing Medical Science and Technique noninvasive tests (NITs) including the fibrosis index based on Development Foundation (QRX17121). the four factors (FIB-4), aspartate aminotransferase–alanine aminotransferase ratio index, aspartate aminotransferase- Conflicts of interest to-platelet ratio index (APRI), and age–platelet index for There are no conflicts of interest. the detection of advanced fibrosis (F3–F4) in 239 chronic hepatitis B (CHB) patients. They could not confirm a reliable clinical utility for these NITs for prediction of advanced References fibrosis in CHB patients with a predominantly Caucasian 1 Lang S, Kütting F, Staub A, Schramowski J, Schramm C, Kasper P, et al. population [1]. The study is very interesting. However, the Performance of simple noninvasive scoring systems for the prediction of advanced fibrosis in patients with chronic hepatitis B. Eur J Gastroenterol results should be interpreted with cautions. Hepatol 2017; 29:1235–1240. First, platelet count is an important component in most 2 Zencir C, Akpek M, Senol S, Selvi M, Onay S, Cetin M, et al. Association of the NITs in the study [1]. The platelets are easily affected between hematologic parameters and in-hospital mortality in patients by many factors such as infections, chronic inflammatory with infective endocarditis. Kaohsiung J Med Sci 2015; 31:632–638. 3 Shiha G, Ibrahim A, Helmy A, Sarin SK, Omata M, Kumar A, et al. Asian- diseases, some hematological disorders, and drug use [2–4]. Pacific Association for the Study of the Liver (APASL) consensus However, the authors only excluded the patients with guidelines on invasive and non-invasive assessment of hepatic fibrosis: a coexisting viral infection and alcohol abuse [1]. The patients 2016 update. Hepatol Int 2017; 11:1–30. were not evaluated for the existence of comorbidities such as 4 Tseng PL, Wang JH, Hung CH, Tung HD, Chen TM, Huang WS, et al. chronic inflammatory diseases and hematological disorders, Comparisons of noninvasive indices based on daily practice parameters for predicting liver cirrhosis in chronic hepatitis B and hepatitis C patients which might have affected the results. in hospital and community populations. Kaohsiung J Med Sci 2013; Second, in the study by Lang et al. [1], CHB patients 29:385–395. were divided into two groups according to the stage of 5WHO. Guidelines for the prevention, care and treatment of persons with fibrosis by liver biopsy: mild fibrosis (F0–F2) and chronic hepatitis B infection. Geneva, Switzerland: World Health Organization; advanced fibrosis (F3–F4). The authors used 0.5 (low cutoff values) and 1.5 (high cutoff values) to distinguish DOI: 10.1097/MEG.0000000000001020 F0–F2 and F3–F4 for APRI, 1.45 (low cutoff values) and European Journal of Gastroenterology & Hepatology 2018, 30:241 0954-691X Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved. 241 Copyright r 2018 Wolters Kluwer Health, Inc. All rights reserved. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Gastroenterology & Hepatology Wolters Kluwer Health

Simple noninvasive tests for the detection of advanced liver fibrosis in patients with chronic hepatitis B

Free
1 page

Loading next page...
1 Page
 
/lp/wolters_kluwer/simple-noninvasive-tests-for-the-detection-of-advanced-liver-fibrosis-CePe0GsdJE
Publisher
Wolters Kluwer
Copyright
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
0954-691X
eISSN
1473-5687
D.O.I.
10.1097/MEG.0000000000001020
Publisher site
See Article on Publisher Site

Abstract

Letter to the Editor 3.25 (high cutoff values) to distinguish F0–F2 and F3–F4 Simple noninvasive tests for the detection of for FIB-4 [1]. However, the above thresholds of APRI and advanced liver fibrosis in patients with chronic FIB-4 are recommended for diagnosing significant fibrosis hepatitis B (≥ F2) rather than advanced fibrosis (F3–F4) in the WHO guidelines for CHB [5]. Thus, the results might be biased if a c d b a Rui Huang , Xiang-An Zhao , Jian Wang , Yingying Hao and Chao Wu , a b the authors used these thresholds for diagnosing advanced Departments of Infectious Diseases, Intensive Care Unit, Nanjing Drum Tower fibrosis (F3–F4). Hospital, Nanjing University Medical School, Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Therefore, large-scale studies with well-defined inclusion Medicine, Nanjing University of Chinese Medicine and Department of Infectious and exclusion criteria are required to validate the diagnostic Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical accuracy of NITs and establish optimal thresholds for the University, Nanjing, Jiangsu Province, China detection of different fibrosis stages in CHB patients. Correspondence to Chao Wu, MD, PhD, Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School, 321 Zhongshan Acknowledgements Road, Nanjing 210008, Jiangsu Province, China Tel: + 86 258 310 5890; fax: + 86 258 330 7115; e-mail: dr.wu@nju.edu.cn The study was supported from the National Natural Science Foundation of China (81672025 and 81702011), Medical Science and Technology Development Foundation of Received 11 October 2017 Accepted 12 October 2017 Nanjing (ZDX16004 and YKK16118), Jiangsu Provincial Medical Innovation Team (CXTDA2017005), Natural We read with great interest the article by Lang et al. [1] in Science Foundation of Jiangsu Province for Young Scholar which they analyzed the diagnostic performance of simple (BK20160121), and Nanjing Medical Science and Technique noninvasive tests (NITs) including the fibrosis index based on Development Foundation (QRX17121). the four factors (FIB-4), aspartate aminotransferase–alanine aminotransferase ratio index, aspartate aminotransferase- Conflicts of interest to-platelet ratio index (APRI), and age–platelet index for There are no conflicts of interest. the detection of advanced fibrosis (F3–F4) in 239 chronic hepatitis B (CHB) patients. They could not confirm a reliable clinical utility for these NITs for prediction of advanced References fibrosis in CHB patients with a predominantly Caucasian 1 Lang S, Kütting F, Staub A, Schramowski J, Schramm C, Kasper P, et al. population [1]. The study is very interesting. However, the Performance of simple noninvasive scoring systems for the prediction of advanced fibrosis in patients with chronic hepatitis B. Eur J Gastroenterol results should be interpreted with cautions. Hepatol 2017; 29:1235–1240. First, platelet count is an important component in most 2 Zencir C, Akpek M, Senol S, Selvi M, Onay S, Cetin M, et al. Association of the NITs in the study [1]. The platelets are easily affected between hematologic parameters and in-hospital mortality in patients by many factors such as infections, chronic inflammatory with infective endocarditis. Kaohsiung J Med Sci 2015; 31:632–638. 3 Shiha G, Ibrahim A, Helmy A, Sarin SK, Omata M, Kumar A, et al. Asian- diseases, some hematological disorders, and drug use [2–4]. Pacific Association for the Study of the Liver (APASL) consensus However, the authors only excluded the patients with guidelines on invasive and non-invasive assessment of hepatic fibrosis: a coexisting viral infection and alcohol abuse [1]. The patients 2016 update. Hepatol Int 2017; 11:1–30. were not evaluated for the existence of comorbidities such as 4 Tseng PL, Wang JH, Hung CH, Tung HD, Chen TM, Huang WS, et al. chronic inflammatory diseases and hematological disorders, Comparisons of noninvasive indices based on daily practice parameters for predicting liver cirrhosis in chronic hepatitis B and hepatitis C patients which might have affected the results. in hospital and community populations. Kaohsiung J Med Sci 2013; Second, in the study by Lang et al. [1], CHB patients 29:385–395. were divided into two groups according to the stage of 5WHO. Guidelines for the prevention, care and treatment of persons with fibrosis by liver biopsy: mild fibrosis (F0–F2) and chronic hepatitis B infection. Geneva, Switzerland: World Health Organization; advanced fibrosis (F3–F4). The authors used 0.5 (low cutoff values) and 1.5 (high cutoff values) to distinguish DOI: 10.1097/MEG.0000000000001020 F0–F2 and F3–F4 for APRI, 1.45 (low cutoff values) and European Journal of Gastroenterology & Hepatology 2018, 30:241 0954-691X Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved. 241 Copyright r 2018 Wolters Kluwer Health, Inc. All rights reserved.

Journal

European Journal of Gastroenterology & HepatologyWolters Kluwer Health

Published: Feb 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off